Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anti-CD73 immunotherapy: A viable way to reprogram the tumor microenvironment.

Literature DB >> 27757316

Anti-CD73 immunotherapy: A viable way to reprogram the tumor microenvironment.

Luca Antonioli¹, Corrado Blandizzi², Fabio Malavasi³, Davide Ferrari⁴, György Haskó⁵.

Abstract

The ecto-5'-nucleotidase/CD73 enzyme plays a pivotal role in generating an adenosine-enriched immunosuppressed and pro-angiogenic niche supporting cancer development. The targeting of CD73 leads to reorganization of tumor microenvironment, shaping the phenotype of the infiltrating T cells. The development of CD73 monoclonal antibodies offers a promising new avenue for antineoplastic treatment.

Entities: Chemical Disease Gene

Keywords: CD73; autophagy; immunotherapy; monoclonal antibody; tumor microenvironment

Year: 2016 PMID： 27757316 PMCID： PMC5048762 DOI： 10.1080/2162402X.2016.1216292

Source DB: PubMed Journal: Oncoimmunology ISSN： 2162-4011 Impact factor: 8.110

10 in total

1. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine.

Authors: J Blay; T D White; D W Hoskin
Journal: Cancer Res Date: 1997-07-01 Impact factor: 12.701

2. Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance.

Authors: Federico Pietrocola; Jonathan Pol; Erika Vacchelli; Shuan Rao; David P Enot; Elisa E Baracco; Sarah Levesque; Francesca Castoldi; Nicolas Jacquelot; Takahiro Yamazaki; Laura Senovilla; Guillermo Marino; Fernando Aranda; Sylvère Durand; Valentina Sica; Alexis Chery; Sylvie Lachkar; Verena Sigl; Norma Bloy; Aitziber Buque; Simonetta Falzoni; Bernhard Ryffel; Lionel Apetoh; Francesco Di Virgilio; Frank Madeo; Maria Chiara Maiuri; Laurence Zitvogel; Beth Levine; Josef M Penninger; Guido Kroemer
Journal: Cancer Cell Date: 2016-07-11 Impact factor: 31.743

3. Anti-CD73 in cancer immunotherapy: awakening new opportunities.

Authors: Luca Antonioli; Gennady G Yegutkin; Pál Pacher; Corrado Blandizzi; György Haskó
Journal: Trends Cancer Date: 2016-02-01

4. Prolonged fasting reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression.

Authors: Chia-Wei Cheng; Gregor B Adams; Laura Perin; Min Wei; Xiaoying Zhou; Ben S Lam; Stefano Da Sacco; Mario Mirisola; David I Quinn; Tanya B Dorff; John J Kopchick; Valter D Longo
Journal: Cell Stem Cell Date: 2014-06-05 Impact factor: 24.633

Review 5. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.

Authors: Jonathan M Pitt; Marie Vétizou; Romain Daillère; María Paula Roberti; Takahiro Yamazaki; Bertrand Routy; Patricia Lepage; Ivo Gomperts Boneca; Mathias Chamaillard; Guido Kroemer; Laurence Zitvogel
Journal: Immunity Date: 2016-06-21 Impact factor: 31.745

Review 6. CD73-adenosine: a next-generation target in immuno-oncology.

Authors: David Allard; Bertrand Allard; Pierre-Olivier Gaudreau; Pavel Chrobak; John Stagg
Journal: Immunotherapy Date: 2016-01-25 Impact factor: 4.196

Review 7. Immunity, inflammation and cancer: a leading role for adenosine.

Authors: Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal: Nat Rev Cancer Date: 2013-11-14 Impact factor: 60.716

Review 8. Tumor microenvironment: a new treatment target for cancer.

Authors: Ming-Ju Tsai; Wei-An Chang; Ming-Shyan Huang; Po-Lin Kuo
Journal: ISRN Biochem Date: 2014-04-10

9. Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action.

Authors: James C Geoghegan; Gundo Diedrich; Xiaojun Lu; Kim Rosenthal; Kris F Sachsenmeier; Herren Wu; William F Dall'Acqua; Melissa M Damschroder
Journal: MAbs Date: 2016-02-08 Impact factor: 5.857

10. Targeting CD73 in the tumor microenvironment with MEDI9447.

Authors: Carl M Hay; Erin Sult; Qihui Huang; Kathy Mulgrew; Stacy R Fuhrmann; Kelly A McGlinchey; Scott A Hammond; Raymond Rothstein; Jonathan Rios-Doria; Edmund Poon; Nick Holoweckyj; Nicholas M Durham; Ching Ching Leow; Gundo Diedrich; Melissa Damschroder; Ronald Herbst; Robert E Hollingsworth; Kris F Sachsenmeier
Journal: Oncoimmunology Date: 2016-07-11 Impact factor: 8.110

10 in total

17 in total

1. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.

Authors: L Buisseret; S Pommey; B Allard; S Garaud; M Bergeron; I Cousineau; L Ameye; Y Bareche; M Paesmans; J P A Crown; A Di Leo; S Loi; M Piccart-Gebhart; K Willard-Gallo; C Sotiriou; J Stagg
Journal: Ann Oncol Date: 2018-04-01 Impact factor: 32.976

Anti-CD73 immunotherapy: A viable way to reprogram the tumor microenvironment.

1. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine.

2. Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance.

3. Anti-CD73 in cancer immunotherapy: awakening new opportunities.

4. Prolonged fasting reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression.

Review 5. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.

Review 6. CD73-adenosine: a next-generation target in immuno-oncology.

Review 7. Immunity, inflammation and cancer: a leading role for adenosine.

Review 8. Tumor microenvironment: a new treatment target for cancer.

9. Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action.

10. Targeting CD73 in the tumor microenvironment with MEDI9447.

1. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.

Review 2. Targeting EGFR in Lung Cancer: Current Standards and Developments.

Review 3. New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.

4. Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche.

5. Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors.

Review 6. Tumor Microenvironment-Induced Immunometabolic Reprogramming of Natural Killer Cells.

7. Adenosinergic Signaling Alters Natural Killer Cell Functional Responses.

Review 8. Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy.

Review 9. The relationship between autophagy and the immune system and its applications for tumor immunotherapy.

10. Inhibition of A_2A Adenosine Receptor Signaling in Cancer Cells Proliferation by the Novel Antagonist TP455.